Compare MTRN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRN | IRON |
|---|---|---|
| Founded | 1931 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | MTRN | IRON |
|---|---|---|
| Price | $134.27 | $82.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $145.50 | $108.85 |
| AVG Volume (30 Days) | 145.9K | ★ 530.2K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,733,667,000.00 | N/A |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | $8.26 | N/A |
| P/E Ratio | $145.44 | ★ N/A |
| Revenue Growth | ★ 3.88 | N/A |
| 52 Week Low | $69.10 | $30.82 |
| 52 Week High | $152.99 | $99.50 |
| Indicator | MTRN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 52.53 |
| Support Level | $130.50 | $74.42 |
| Resistance Level | $152.99 | $79.48 |
| Average True Range (ATR) | 4.36 | 3.82 |
| MACD | -1.11 | 0.69 |
| Stochastic Oscillator | 19.54 | 90.02 |
Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.